Search Results - "Martos, C. Fernández"

Session 2: Are we ready for primary chemotherapy in rectal cancer: who, when, why? by Patel, U. B., Cervantes, A., Fernández‐Martos, C., Sclafani, F., Cunningham, D., Nilsson, P., Brown, G.

“…The potential of preoperative chemotherapy in rectal cancer is the subject of investigation in a number of global randomized trials. In this overview and…”
Get full text

SEOM Clinical Guideline of localized rectal cancer (2016) by González-Flores, E., Losa, F., Pericay, C., Polo, E., Roselló, S., Safont, M. J., Vera, R., Aparicio, J., Cano, M. T., Fernández-Martos, C.

“…Localized rectal adenocarcinoma is a heterogeneous disease and current treatment recommendations are based on a preoperative multidisciplinary evaluation…”
Get full text

SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer by García-Carbonero, R., Vera, R., Rivera, F., Parlorio, E., Pagés, M., González-Flores, E., Fernández-Martos, C., Corral, M. Á., Bouzas, R., Matute, F.

“…Colorectal cancer (CRC) is one of the world’s most common cancers, and has one of the highest mortality rates. The last few decades have seen great progress in…”
Get full text

Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial by Fernandez-Martos, C., Garcia-Albeniz, X., Pericay, C., Maurel, J., Aparicio, J., Montagut, C., Safont, M.J., Salud, A., Vera, R., Massuti, B., Escudero, P., Alonso, V., Bosch, C., Martin, M., Minsky, B.D.

“…The primary results of our phase II randomized trial suggested that compared with conventional preoperative chemoradiation (CRT), the addition of chemotherapy…”
Get full text

Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer by Aparicio, J., Vicent, J. M., Maestu, I., Garcerá, S., Busquier, I., Bosch, C., Llorca, C., Díaz, R., Fernández-Martos, C., Galán, A.

“…Background: Irinotecan (CPT-11) and raltitrexed are active against advanced colorectal cancer (ACC), act through different mechanisms, and have only partially…”
Get full text

AVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02) by Español Rego, M., Alonso, V., Aparicio, J., Elez Fernandez, E., Escudero, P., Fernández-Martos, C., Rodríguez, N., Ruiz Casado, A., Cid, J., Cabezón, R., Lozano, M., Ginés, A., Bianchi, L., Garcia-Corbacho, J., García de Albéniz, X., Maurel, J., Benitez Ribas, D.

Get full text

Prospective biomarker study in advanced RAS wild-type colorectal cancer: POSIBA trial by García Albéniz, X, Alonso, V, Escudero, P, Méndez, M, Gallego Plazas, J, Rodriguez, J R, Salud Salvia, A, Fernández-Plana, J, Manzano Alemany, H, Zanui, M, Falcó, E, Feliu Batlle, J, Gil-Raga, M, Fernández-Martos, C, Bohn Sarmiento, U, Alonso López, M C, Calderero Aragón, V, Rojo, F, Cuatrecasas, M, Maurel, J

Get full text

Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy: Combined analysis of two prospective clinical trials by Montagut, C, Alonso, V, Escudero, P, Fernández-Martos, C, Salud Salvia, A, Méndez, M, Gallego Plazas, J, Rodriguez, J R, Martín-Richard, M, Fernández-Plana, J, Aparicio, J, Feliu Batlle, J, García de Albéniz, X, Rojo, F, Fernández, V, Claes, B, Maertens, G G, Sablon, E, Jacobs, B A W, Maurel, J

Get full text

MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial by Patel, U.B., Brown, G., Machado, I., Santos-Cores, J., Pericay, C., Ballesteros, E., Salud, A., Isabel-Gil, M., Montagut, C., Maurel, J., Ramón-Ayuso, J., Martin, N., Estevan, R., Fernandez-Martos, C.

“…Primary chemotherapy has been tested as a possible approach for patients with high risk features but predicted clear mesorectal margins on preoperative MRI…”
Get full text

PG 1.02 Clinically relevant study end points in rectal cancer by Fernandez-Martos, C

Get full text

Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND) by Aparicio, J., Virgili, A., Capdevila, J., Muñoz Boza, F., Álvarez, R., Bosch, C., Cámara, J., Fernandez-Martos, C., Fernandez-Plana, J., Gallego, J., Gallego, R., Hernández-Yagüe, X., Macías Declara, I., Rodríguez-Salas, N., Vera, R., Taberner, M., Maurel, J.

Get full text

Wnts are expressed in the spinal cord of adult mice and are differentially induced after injury by González-Fernández, Carlos, Fernández-Martos, Carmen María, Shields, Shannon D, Arenas, Ernest, Javier Rodríguez, Francisco

“…The Wnt family of proteins plays key roles during central nervous system development and has been involved in several neuropathologies during adulthood,…”
Get more information

Differential expression of Wnts after spinal cord contusion injury in adult rats by Fernández-Martos, Carmen María, González-Fernández, Carlos, González, Pau, Maqueda, Alfredo, Arenas, Ernest, Rodríguez, Francisco Javier

“…Spinal cord injury is a major cause of disability that has no clinically accepted treatment. Functional decline following spinal cord injury is caused by…”
Get full text

2161 The prognostic significance of radiologic and pathologic factors after neoadyuvant chemotherapy for T3 rectal cancer (RC): 3-years update GEMCAD 0801 trial by Machado, I, Patel, U, Brown, G, Salud, A, Gil, M, Montagut, C, Busto, M, Safont, M, Maurel, J, Ayuso, J, Aparicio, J, Feliu, J, Vera, R, Alonso, V, Gallego, J, Martin, M, Pericay, C, Ballesteros, E, Santos, J, Fernandez-Martos, C

Get full text

442P A phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. GEMCAD 16-02 (AVEVAC trial) by Español-Rego, M., Fernández-Martos, C., Fernandez, M.E. Elez, Foguet, C., Pedrosa, L., Rodríguez, N., Ruiz, A., Pineda, E., Cid, J., Cabezón, R., Oliveres, H., Lozano, M., Ginés, A., Garcia-Criado, A., Cuatrecasas, M., Torres, F., Cascante, M., Benítez-Ribas, D., Maurel, J.

Get full text

471P Identification and validation of a new prognostic score in metastatic colorectal cancer (mCRC): GEMCAD score by Seguí, E., Alonso-Orduna, V., Sesma, A., Martin-Richard, M., Salud, A., Fernández-Montes, A., Fernández-Martos, C., Ruiz-Casado, A., Gallego, J., Aparicio, J., Gálvez, E., Manzano, H., Alcaide-Garcia, J., Gallego, R., Falco, E., Esposito, F., Oliveres, H., Torres, F., Feliu, J., Maurel, J.

Get full text

474P Prognostic and predictive role of Consensus Molecular Subtypes (CMS) determined by immunohistochemistry in metastatic colorectal cancer (mCRC) by Gomez, O. Higuera, Soto, V. Heredia, Machado, I., Mendez, M.C., Cuatrecasas, M., Horndler, C., Vermeulen, L., Hoorn, S. Ten, Mendiola, M., Martín-Richard, M., Ruiz-Casado, A., Galvez, E., Aparicio, J., García, I. Sevilla, Leno, R., Fernández-Martos, C., Alonso-Orduna, V., Montes, A. Fernandez, Maurel, J., Feliu, J.

Get full text

Spatio-temporal expression pattern of frizzled receptors after contusive spinal cord injury in adult rats by Gonzalez, Pau, Fernandez-Martos, Carmen Maria, Gonzalez-Fernandez, Carlos, Arenas, Ernest, Rodriguez, Francisco Javier

“…Wnt proteins are a large family of molecules that are critically involved in multiple central nervous system (CNS) developmental processes. Experimental…”
Get full text

The Ryk receptor is expressed in glial and fibronectin-expressing cells after spinal cord injury by González, Pau, Fernández-Martos, Carmen María, Arenas, Ernest, Rodríguez, Francisco Javier

“…Wnt proteins play a critical role in central nervous system development and have been implicated in several neuropathologies, including spinal cord injury…”
Get more information

Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial by Aranda, E., Cervantes, A., Carrato, A., Fern´ndez-Martos, C., Antón-Torres, A., Massutí, T., Barneto, I., García-Conde, J., Barón, J. M, Díaz-Rubio, E.

“…Background: Background: In a previous phase I–II trial we showed that maximum tolerable dose (MTD) of 5-fluorouracil (5-FU) a weekly 48-hour continuous…”
Get full text